Find Novel Oncology Drugs in Discovery in UNITED STATES

Lead Product(s): T-cell bispecific antibodies

Therapeutic Area: Oncology

Highest Development Status: Discovery Product Type: Large molecule

Partner/Sponsor/Collaborator: Astellas

Deal Size: $1,600.0 million Upfront Cash: $80.0 million

Deal Type: Collaboration March 23, 2020

Details:

Under this collaboration, the parties will utilize CytomX’s Probody® therapeutic technology platform, as well as its proprietary bispecific formats and CD3 modules.

Lead Product(s): XTX201

Therapeutic Area: Oncology

Highest Development Status: Discovery Product Type: Large molecule

Partner/Sponsor/Collaborator: Takeda Ventures

Deal Size: $100.5 million Upfront Cash: Undisclosed

Deal Type: Series B Financing March 02, 2020

Details:

Proceeds from the financing will be used to progress Xilio’s first two therapeutic candidates, XTX201 and XTX101 through Investigational New Drug enabling studies and into Phase 1 clinical trials.